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Table 1. Coefﬁcients of Variation in Cardiology Practice
Measurement First Author (Ref. #)
Coefﬁcient
of Variation
FFR Berry et al. (4) 3%
Fasting plasma glucose Mooy et al. (6) 9%
Ambulatory systolic blood pressure Eguchi et al. (7) 11%
LDL Miller et al. (8) 6%–14%
Ejection fraction by MRI Grothues et al. (9) 12%
Percent diameter stenosis by QCA Reiber et al. (10) 17%–18%
CRP Bower et al. (11) 46%
CRP ¼ C-reactive protein; FFR ¼ fractional-ﬂow reserve; LDL ¼ low-density lipoprotein;
MRI ¼ magnetic resonance imaging; QCA ¼ quantitative coronary angiography.
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Petraco et al. (1) raise a universal issue that affects all clinical tests.
Every binary cutoff produces cases just on either side of the
threshold for whom a repeat measurement might alter the deci-
sion, no matter how accurate the test or how small its variability.
By analogy to a Gaussian distribution of observations about the
true value, the critical measure for any diagnostic test remains the
“width” of that curve. Indeed, the topic predates the concept of
fractional ﬂow reserve (FFR). Measurement repeatability came to
attention almost 25 years ago when thresholds were proposed
for total cholesterol (2). Therefore, although the core statistical
issue also applies to FFR by deﬁnition, we have fundamental
concerns regarding Petraco and colleagues’ (1) method and con-
clusions in this speciﬁc case.
First, Petraco et al. (1) extracted repeated FFR measurements
from a digitized ﬁgure instead of using the raw data or its pub-
lished, analyzed results. Given overlap and clustering in the scatter
plot, we suspect they could extract at most one-half to two-thirds of
the data points. As a result, they incorrectly estimate the SD of the
difference between repeated FFR measurements as 0.032 when the
original publication stated 0.02 using the raw data (3). Further-
more, those FFR measurements obtained at least 15 years ago used
prior-generation pressure wires, including ﬁber-optic technology
with more drift, all technically inferior to modern FFR wires.
Second, the recent VERIFY (VERiﬁcation of Instantaneous
Wave-Free Ratio and Fractional Flow Reserve for the Assessment
of Coronary Artery Stenosis Severity in EverydaY Practice) study
(4) also found the SD between repeated FFR measurements to be
0.02. Therefore, it is very unlikely that a lesion’s FFR measure-
ment will change from <0.75 (deﬁnitively ischemic) to >0.80
(deﬁnitively not ischemic) or vice versa upon repeat measurement.
Such a change would be >3 SD (0.81  0.74 ¼ 0.07, which is
larger than 3 SD, or 3  0.02), which would occur <0.3% of the
time. For example, in the VERIFY trial, no subject (0%) crossed
between FFR <0.75 and FFR >0.80dindeed, no subject crossed
between 0.75 and 0.80.
Finally, the universal considerations regarding measurement
variability apply even more to the instantaneous wave-free ratio
(iFR). The VERIFY study demonstrated 95% limits of agreement
for repeated FFR measurements of 0.04dmuch narrower than
the wider 0.07 variability in iFR (4). Similarly, in the VERIFY
trial, FFR 0.80 agreed with itself 95% of the time, whereas iFR
0.89 agreed with itself only 92% of the time.
To account for both biological variability and measurement
uncertainty, we have never advocated a single cutoff, but have rather
clearly stated that FFR possesses “a narrow cut-off value discrim-
inating ischaemic stenoses” but “in the grey zone, between 0.76
and 0.80, decision making should be based upon sound clinical
judgement, typicality of complaints, presence of other test results”
(5), and myocardial mass at risk.
In conclusion, Table 1 demonstrates that FFR offers one of
the most reproducible numbers in cardiology practice, as quantiﬁedby its coefﬁcient of variation (extent of variability around the typi-
cal value) for repeated measurements (4,6–11). If only every test
we rely on daily for clinical decisions would have the narrow
“gray zone” offered by FFR, our lives would be far more black
and white.
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Reply
Fractional Flow Reserve: A Good or a Gold
Standard?“Coronary pressure NEVER lies.”
dKoolen and Pijls (1)
0.81, or indeed defer some wit
automatically irresponsible or car“.the authors took the responsibility and conse-
quences of their actions by STRICTLY adhering to
treating patients with FFR <0.80 and deferring
patients with FFR >0.80.”
dPijls and Tonino (2)
Sayan Sen, MB BS
Mauro Echavarria-Pinto, MDWe thank Dr. Johnson and colleagues and Dr. Fan and col-
leagues for their interest in our work (3).
Fractional ﬂow reserve (FFR) has come a long way over the last
20 years, from an upstart to what is now commonly proposed as
an infallible gold standard for the detection of myocardial ischemia.
The brilliance of the pioneer clinical scientists who forged their way
forward against skepticism may understandably have moved them
to exceptional heights of eloquence and may explain why the
inherent limitations of this valuable technique have never been
openly discussed. Our reﬂections on FFR variability (3) do not
question the value of FFR, a tool that we use every day in our
laboratory as a guide to treatment decisions. We simply addressed
the potential limitations of a dichotomous interpretation of FFR
results. Our aim was to help clinicians see that FFR, like all other
measurements in medicine, does not carry strict dichotomous im-
plications for which treatment is best, and this is especially true
close to the cutoff.
Dr. Johnson and colleagues point out that we used only the
data salvaged from oblivion through publication by Kern et al.
(4), because the original DEFER study data seem to have been
mislaid, unfortunatelydan increasingly common problem with
pivotal FFR datasets. They are also right that our methodology
perhaps inﬂuenced our results. However, may we correct them:we underestimated FFR variability (SD of difference) at only
3.2%. The DEFER study reported only mean absolute difference,
from which SD of difference can be derived as 3.7%. We have
explored this issue in more details in a recent publication (5),
from which readers can test the FFR intrinsic variability in their
own samples.
Dr. Johnson and colleagues and Dr. Fan and colleagues also
cast doubts on our analysis because of the old pressure guidewire
technology used in the DEFER study. Do they suggest that the
positive results of the DEFER study should be re-examined?
Also, should these concerns be extended to the validity of other
early pivotal FFR studies? We should recall that the most
important piece of evidence on the diagnostic efﬁciency of FFR in
identifying ischemia-generating stenoses comes from a study of 46
patients, investigated nearly 20 years ago with even older pressure
wires (6). Reassuringly, using state-of-the art wire technology,
Ntalianis et al. (7) recently reported the test–retest variability of
FFR to be 5% when taken more than 24 h apart, demonstrating
elegantly that FFR measurement variability is a true biological
phenomenon.
We do agree with Dr. Fan and colleagues that clinicians should
assess test–retest reproducibility of FFR in their own hands and
make repeated measurements of FFR when facing intermediate
values. We merely recommend parsimony, both with adenosine
and with references to golden infallibility. Clinicians must inte-
grate many aspects of lesion and patient characteristics into their
decisions. If clinicians sometimes stent stenoses with an FFR ¼
h an FFR ¼ 0.74, they are not
eless.
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